Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
AAV9 viral vector containing HEXA and HEXB genes
(TSHA-101) /
Taysha Gene Therapies
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
AAV9 viral vector containing HEXA and HEXB genes
(TSHA-101) /
Taysha Gene Therapies
Trial primary completion date, Gene therapy:
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
(clinicaltrials.gov) - May 9, 2023
P1/2
, N=3, Active, not recruiting,
Sponsor: Dr. Anupam Sehgal
Trial primary completion date: Mar 2023 --> Mar 2027
||||||||||
AAV9 viral vector containing HEXA and HEXB genes
(TSHA-101) /
Taysha Gene Therapies
Enrollment closed, Gene therapy:
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
(clinicaltrials.gov) - Sep 14, 2022
P1/2
, N=3, Active, not recruiting,
Sponsor: Dr. Anupam Sehgal
Trial primary completion date: Mar 2023 --> Mar 2027 Suspended --> Active, not recruiting
||||||||||
AAV9 viral vector containing HEXA and HEXB genes
(TSHA-101) /
Taysha Gene Therapies
Trial suspension, Gene therapy:
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
(clinicaltrials.gov) - May 11, 2022
P1/2
, N=6, Suspended,
Sponsor: Dr. Anupam Sehgal
Suspended --> Active, not recruiting Active, not recruiting --> Suspended
||||||||||
AAV9 viral vector containing HEXA and HEXB genes
(TSHA-101) /
Taysha Gene Therapies
Enrollment closed, Gene therapy:
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
(clinicaltrials.gov) - Apr 11, 2022
P1/2
, N=6, Active, not recruiting,
Sponsor: Dr. Anupam Sehgal
Active, not recruiting --> Suspended Recruiting --> Active, not recruiting
|
|||||||||
AAV9 viral vector containing HEXA and HEXB genes
(TSHA-101) /
Taysha Gene Therapies
Enrollment open, Gene therapy:
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
(clinicaltrials.gov) - Mar 18, 2021
P1/2
, N=6, Recruiting,
Sponsor: Dr. Anupam Sehgal
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
|
|||||||||
AAV9 viral vector containing HEXA and HEXB genes
(TSHA-101) /
Taysha Gene Therapies
New P1/2 trial, Gene therapy:
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
(clinicaltrials.gov) - Mar 15, 2021
P1/2
, N=6, Not yet recruiting,
Sponsor: Dr. Anupam Sehgal